Category Archives: Cell Medicine


Cell Signaling Technology, Inc. Develops Novel Monoclonal Antibody Discovery Platform

DANVERS, Mass.–(BUSINESS WIRE)– Cell Signaling Technology, Inc. (CST) of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , | Comments Off

Regenerative medicine: Could the ways animals regenerate hair and feathers help restore human fingers and toes?

ScienceDaily (May 10, 2012) This summer’s action film, “The Amazing Spider-Man,” is another match-up between the superhero and his nemesis the Lizard. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , | Comments Off

Study Identifies Cell Subtypes For Potential Personalized Cellular Therapies

Connie K. Ho for RedOrbit.com A new study by researchers at the University of California, Los Angeles (UCLA) has discovered two adult stem cell-like subpopulations in adult human skin. The findings allow for further research to be done in the area of personalized medicine and patient-specific cellular therapies Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , | Comments Off

Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed …

SEATTLE, May 10, 2012 /PRNewswire/ — Cell Therapeutics, Inc.(“CTI”) (CTIC) today announced that it has received conditional marketing authorization from the European Commission (“EC”) for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (“NHL”). Continue reading

Posted in Cell Medicine | Tagged , , , , , , , | Comments Off

New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly …

BOUDRY, Switzerland–(BUSINESS WIRE)– Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG – News), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine. All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas. Continuous Lenalidomide Therapy (non-transplant eligible population): The first article highlights a Celgene-sponsored study of continuous lenalidomide treatment in elderly patients newly diagnosed with multiple myeloma. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , | Comments Off

Navigating the IP Minefield of Human Embryonic Stem Cell Development

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ — Global Information Inc. is pleased to announce two significant new reports Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , , , | Comments Off

Research and Markets: Biomedical Sciences: Essential Laboratory Medicine

DUBLIN–(BUSINESS WIRE)– Dublin – Research and Markets (http://www.researchandmarkets.com/research/t99fl5/biomedical_science) has announced the addition of John Wiley and Sons Ltd’s new book “Biomedical Sciences: Essential Laboratory Medicine” to their offering. Biomedical Sciences is an indispensable, all encompassing core textbook for first/ second year biomedical science students that will support them throughout their undergraduate career. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , , , | Comments Off

Research and Markets: Skeletal Biology and Medicine I: Mechanisms Regulating Bone Mass

DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/4zkdn4/skeletal_biology_a) has announced the addition of John Wiley and Sons Ltd’s new book “Skeletal Biology and Medicine I: Mechanisms Regulating Bone Mass” to their offering. The volume features current basic, clinical, and translational research on aspects of skeletal morphogenesis and remodeling in health and disease. Papers survey vital new insights into the mechanisms of bone development and restructuring, including cellular and mechanical triggers, receptors and signaling pathways. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , , | Comments Off

Advanced Cell Technology to Host Conference Call to Discuss 2012 First Quarter Results and Provide Corporate Update on …

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , , | Comments Off

Advanced Cell Technology Announces 2012 First Quarter Results

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012 Continue reading

Posted in Cell Medicine | Tagged , , , , , , , , , , , | Comments Off